# A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07229872/  
OnCo record `nct07229872` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fruquintinib in colorectal cancer, run by Harbin Medical University, not yet recruiting.

## Summary

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment is a phase 2, interventional study registered as NCT07229872 by Harbin Medical University, with a registry enrolment figure of 18 participants, started 2025-12 and due to reach its primary completion in 2026-12. Interventions recorded: Aipalolitovorelizumab; Fruquintinib. Conditions listed: Colorectal Cancer. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "Patients must be pathologically confirmed as advanced, metastatic or recurrent microsatellite stable (MSS) colorectal cancer (detected by immunohistochemistry, PCR or NGS according to the detection standards of each institutional testing center);". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07229872
- Phase: 2
- Setting: A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment
- Sponsor: Harbin Medical University
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT07229872: https://clinicaltrials.gov/study/NCT07229872

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07229872.json